New hope for brain cancer: experimental virus therapy targets aggressive tumors

NCT ID NCT06504381

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and after surgery, plus standard care. The goal is to see if the combination improves survival and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2 glioblastoma glioma IDH-wildtype glioblastoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA MGMT-METHYLATED GLIOBLASTOMA MGMT-UNMETHYLATED GLIOBLASTOMA

Contacts and locations

Show contact details

Locations

Northwell Health
RECRUITING

Lake Success, New York, 11042, United States
University of California
RECRUITING

San Francisco, California, 94143, United States
University of California, San Diego
RECRUITING

San Diego, California, 92093, United States

Contact Email: •••••@•••••
University of Miami
RECRUITING

Miami, Florida, 33136, United States
University of Southern California
RECRUITING

Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.